September 16, 2025 11:45 ET | Source: Transgene S.A. Transgene S.A.
RAPPORT SEMESTRIEL 2025
Pièce jointe
Transgene to Present Preclinical Data Demonstrating Robust Protection Against Mpox with its Novel Scalable Cell Line–Derived MVA Vaccine Candidate at WCID
Transgene Expands myvac® into Non-Small Cell Lung Cancer with TG4070, an Individualized Neoantigen Therapeutic Vaccine
